Drug Approval | September 04, 2021
Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across eight sites in Maharashtra
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
The transaction is expected to close in the Q4FY22
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
